# BioMarin Pharmaceutical Inc. (BMRN) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $66.53, market value $12.9 billion.

## Valuation
- **P/E (trailing): 179.8×** (5-yr avg 77.9×, 3-yr avg 57.9×). BioMarin Pharmaceutical Inc. trades at 179.8× trailing earnings, well above its own five-year average of 77.9×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 10.2×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 3.8×**. Each dollar of revenue is priced at 3.8×.
- **Price / book: 2.0×**. The shares trade at 2.0× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 40.2×**. Enterprise value is 40.2× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 5.7%** (5-yr avg 2.4%). Free cash flow equals 5.7% of the market value, above its five-year average of 2.4%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 0.6%**. The inverse of the P/E: 0.6% of the price is earned each year.

## Profitability
- **Operating margin: 4.4%**. 4.4% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 10.8%**. 10.8% of each dollar of sales reaches the bottom line.
- **Return on equity: 5.7%**. 5.7% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 2.2%**. Return on all capital, debt included, is 2.2%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 1.0%**. Each dollar of assets produces 1.0% of profit.

## Growth
- **Revenue growth (1 yr): 12.9%** (3-yr 15.4%/yr, 5-yr 11.6%/yr). Revenue grew 12.9% over the last year, against 11.6% a year compounded over five years.
- **EPS growth (1 yr): -18.6%** (3-yr 33.9%/yr, 5-yr -16.7%/yr). Earnings per share fell 18.6%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 136.3%/yr**. Free cash flow has compounded at 136.3% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.10**. Debt is 0.10 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. BioMarin Pharmaceutical Inc. holds more cash than debt.
- **Altman Z-score: 6.85**. A Z-score of 6.85 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. BioMarin Pharmaceutical Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (26 analysts). 26 analysts cover BioMarin Pharmaceutical Inc.; the consensus is buy, with an average price target of $91.04 (+37% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 17.2%** (YTD 11.9%, 3-mo 17.2%). The shares are up 17.2% over twelve months including dividends.
- **From 52-week high: -6.3%** (35.1% above the low). Trading 6% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 56**. An RSI of 56 is neutral.
- **Beta (1 yr): 0.38** (volatility 35%). Beta of 0.38 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BMRN · Page: https://foliofundamentals.com/stocks/bmrn

Not investment advice.